Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: Results from a randomized, placebo-controlled clinical study

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 2, 2010, Pages 197-203

  Sanwald Ducray, P ^a   Liogier D'Ardhuy, X ^a   Jamois, C ^a   Banken, L ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEGLITAZAR; ANTIDIABETIC AGENT; CREATININE; GLUCOSE; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RO 0728804; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIET RESTRICTION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE;

AGED; AREA UNDER CURVE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OXAZOLES; SOCIOECONOMIC FACTORS; THIOPHENES;

EID: 77954887093     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.259     Document Type: Article

References (25)

1. Engelgau, M.M. et al. the evolving diabetes burden in the United states. Ann. Intern. Med. 140, 945-950 (2004).
2. Fox, C.S. et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart study. Circulation 115, 1544-1550 (2007).
3. American Diabetes Association. standards of medical care in diabetes\2009. Diabetes Care 32 (suppl. 1), s13-s61 (2009).
4. Hu, F.B. et al. the impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch. Intern. Med. 161, 1717-1723 (2001).
5. Fox, C.S. et al. trends in cardiovascular complications of diabetes. JAMA 292, 2495-2499 (2004).
6. Saydah, S.H., Fradkin, J. & Cowie, C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291, 335-342 (2004).
7. Efect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDs 34). UK Prospective Diabetes study (UKPDs) group. Lancet 352, 854-865 (1998).
8. Stratton, I.M. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDs 35): prospective observational study. BMJ 321, 405-412 (2000).
9. Selvin, E. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 141, 421-431 (2004).
10. Patel, A. et al.; ADVANCE Collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2572 (2008).
11. Gerstein, H.C. et al.; Action to Control Cardiovascular Risk in Diabetes study group. Efects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
12. Cefalu, W.T. & Watson, K. Intensive glycemic control and cardiovascular disease observations from the ACCORD study: now what can a clinician possibly think? Diabetes 57, 1163-1165 (2008)
13. Dluhy, R.G. & McMahon, G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N. Engl. J. Med. 358, 2630-2633 (2008).
14. Berger, J. & Moller, D.E. the mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435 (2002).
15. Staels, B. & Fruchart, J.C. therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 2460-2470 (2005). (Pubitemid 41134276)
16. Bénardeau, A. et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg. Med. Chem. Lett. 19, 2468-2473 (2009).
17. Balakumar, P., Rose, M., Ganti, S.S., Krishan, P. & Singh, M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res. 56, 91-98 (2007).
18. Henry, R.R., Lincof, A.M., Mudaliar, S., Rabbia, M., Chognot, C. & Herz, M. Efect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (sYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374, 126-135 (2009).
19. Davidson, M.H., Armani, A., McKenney, J.M. & Jacobson, T.A. safety considerations with fbrate therapy. Am. J. Cardiol. 99, 3C-18C (2007)
20. Goldstein, B.J., Rosenstock, J., Anzalone, D., tou, C. & Ohman, K.P. Efect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. 22, 2575-2590 (2006).
21. Aronof, S., Rosenblatt, S., Braithwaite, S., Egan, J.W., Mathisen, A.L. & schneider, R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. the Pioglitazone 001 study group. Diabetes Care 23, 1605-1611 (2000).
22. Lebovitz, H.E., Dole, J.F., Patwardhan, R., Rappaport, E.B. & Freed, M.I.; Rosiglitazone Clinical trials study group. Rosiglitazone monotherapy is efective in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 86, 280-288 (2001)
23. Mudaliar, S., Chang, A.R. & Henry, R.R. thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. 9, 406-416 (2003).
24. World Health Organization. Defnition, diagnosis, and classifcation of diabetes mellitus and its complications. Report of a WHO Consultation (World Health Organization, geneva, switzerland, 1999).
25. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., treacher, D.F. & turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).